GSK's oncology and HIV drugs drive sales growth of 7% in 2025. Sales of specialty drugs, including oncology, Benlysta and Nucala, grew by low double-digit percentages in the third quarter of 2025. Sales of Benlyst, a monoclonal antibody for lupus, were up 15% in the quarter and 18% year-to-date, with total sales of £447m for the quarter and £1,257m for the year. Anemic myelofibrosis Ojjaara/Omjjara grew 51% in the quarter and 69% year-on-year, with sales of £396m. Sales of Zejula for ovarian cancer fell 5% quarter-over-quarter and year-over-year. Blenrep for relapsed/refractory multiple myeloma had sales of £4m in the year after launch. GSK expects an accelerated R&D strategy and new product launches to help offset the impact of patent expirations in the portfolio.[1]